Search Results - "van den Hout, Hannerieke"
-
1
Enzymatic diagnosis of Pompe disease: lessons from 28 years of experience
Published in European journal of human genetics : EJHG (01-03-2021)“…Pompe disease is a lysosomal and neuromuscular disorder caused by deficiency of acid alpha-glucosidase (GAA), and causes classic infantile, childhood onset, or…”
Get full text
Journal Article -
2
The Natural Course of Infantile Pompe's Disease: 20 Original Cases Compared With 133 Cases From the Literature
Published in Pediatrics (Evanston) (01-08-2003)“…Infantile Pompe's disease is a lethal cardiac and muscular disorder. Current developments toward enzyme replacement therapy are promising. The aim of our study…”
Get full text
Journal Article -
3
Broad variation in phenotypes for common GAA genotypes in Pompe disease
Published in Human mutation (01-11-2021)“…Patients with the common c.‐32‐13T > G/null GAA genotype have a broad variation in age at symptom onset, ranging from early childhood to late adulthood…”
Get full text
Journal Article -
4
Up to five years experience with 11 mucopolysaccharidosis type VI patients
Published in Molecular genetics and metabolism (01-05-2013)“…Maroteaux–Lamy syndrome (mucopolysaccharidosis type VI, MPS VI) is a rare progressive metabolic disorder characterized by coarse facial features,…”
Get full text
Journal Article -
5
Tagged IDS causes efficient and engraftment-independent prevention of brain pathology during lentiviral gene therapy for Mucopolysaccharidosis type II
Published in Molecular therapy. Methods & clinical development (14-12-2023)“…Mucopolysaccharidosis type II (OMIM 309900) is a lysosomal storage disorder caused by iduronate 2-sulfatase (IDS) deficiency and accumulation of…”
Get full text
Journal Article -
6
A Generic Assay to Detect Aberrant ARSB Splicing and mRNA Degradation for the Molecular Diagnosis of MPS VI
Published in Molecular therapy. Methods & clinical development (11-12-2020)“…Identification and characterization of disease-associated variants in monogenic disorders is an important aspect of diagnosis, genetic counseling, prediction…”
Get full text
Journal Article -
7
Perioperative management of children with glycogen storage disease type II—Pompe disease
Published in Pediatric anesthesia (01-05-2018)“…Summary Background Pompe disease is a rare metabolic disorder caused by a deficiency of the lysosomal enzyme acid α‐glucosidase. Glycogen accumulation damages…”
Get full text
Journal Article -
8
Morphological changes in muscle tissue of patients with infantile Pompe's disease receiving enzyme replacement therapy
Published in Muscle & nerve (01-06-2003)“…Pompe's disease (glycogen storage disease type II) is an autosomal recessive myopathy caused by lysosomal α‐glucosidase deficiency. Enzyme replacement therapy…”
Get full text
Journal Article -
9
Segmental and total uniparental isodisomy (UPiD) as a disease mechanism in autosomal recessive lysosomal disorders: evidence from SNP arrays
Published in European journal of human genetics : EJHG (01-06-2019)“…Analyses in our diagnostic DNA laboratory include genes involved in autosomal recessive (AR) lysosomal storage disorders such as glycogenosis type II (Pompe…”
Get full text
Journal Article -
10
A genetic modifier of symptom onset in Pompe disease
Published in EBioMedicine (01-05-2019)“…Neonatal screening for Pompe disease is complicated by difficulties in predicting symptom onset in patients with the common c.-32-13T>G (IVS1) variant/null…”
Get full text
Journal Article -
11
Delayed Diagnosis of Danon Disease in Patients Presenting With Isolated Cardiomyopathy
Published in Circulation. Cardiovascular genetics (01-03-2019)Get full text
Journal Article -
12
Hearing loss in infantile Pompe's disease and determination of underlying pathology in the knockout mouse
Published in Neurobiology of disease (01-06-2004)“…Hearing deficit occurs in several lysosomal storage disorders but has so far not been recognized as a symptom of Pompe's disease (glycogen storage disease type…”
Get full text
Journal Article -
13
Efficacy and safety of Velmanase alfa in the treatment of patients with alpha-mannosidosis: results from the core and extension phase analysis of a phase III multicentre, double-blind, randomised, placebo-controlled trial
Published in Journal of inherited metabolic disease (01-12-2018)“…Introduction This phase III, double-blind, randomised, placebo-controlled trial (and extension phase) was designed to assess the efficacy and safety of…”
Get full text
Journal Article -
14
Comprehensive long-term efficacy and safety of recombinant human alpha-mannosidase (velmanase alfa) treatment in patients with alpha-mannosidosis
Published in Journal of inherited metabolic disease (01-11-2018)“…Introduction Long-term outcome data provide important insights into the clinical utility of enzyme replacement therapies. Such data are presented for velmanase…”
Get full text
Journal Article -
15
Anesthesiological approach to the floppy child
Published in Minerva anestesiologica (01-08-2021)Get full text
Journal Article -
16
-
17
Anaesthesiological approach to the floppy child
Published in Minerva anestesiologica (12-01-2021)“…Children with symptoms of hypotonia (reduction of postural tone of lower limbs and trunk with or without changes in phasic tone) are frequently anaesthetized…”
Get full text
Journal Article -
18
Recombinant human α-glucosidase from rabbit milk in Pompe patients
Published in The Lancet (British edition) (29-07-2000)“…Pompe's disease is a fatal muscular disorder caused by lysosomal α-glucosidase deficiency. In an open-label study, four babies with characteristic…”
Get full text
Journal Article -
19
Safety analysis of home-based enzyme replacement therapy with alglucosidase alfa in Pompe disease: A prospective study
Published in Molecular genetics and metabolism (01-02-2023)Get full text
Journal Article -
20
Enzyme therapy for Pompe disease: from science to industrial enterprise
Published in European journal of pediatrics (01-01-2002)“…Pompe disease or glycogen storage disease type II (OMIM 232300) is a metabolic myopathy with a broad clinical spectrum. Generalised muscle weakness combined…”
Get full text
Journal Article